The Phase 1 trial was a randomized, placebo-controlled, double-blind, single-center, first-in-human trial investigating safety, tolerability, and proof-of-concept following single and multiple dosing ...
STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a successful $56 million Series C ...
Lehi, Utah, April 16, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced ...
ATX-011 is mutation-agnostic and engineered for the entire ET population – delivering platelet normalisation - within days - in non-human primate models. Best‑in‑class safety emerging: non-human ...
Roquette Successfully Prices its Hybrid Notes Issuance for an Amount of 600 million Euros ...
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex ...
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications . Berlin, Germany, April 16, 2026, 0 ...
Eurobio Scientific's reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, "Pépites et ...
Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA ® (recombinant, adsorbed) for active immunization for the prevention ...
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on ...
Most recently, Dr Moses served as Chair of Dark Blue Therapeutics, an Oxford-based oncology biotech which was acquired by Amgen in a deal valued at up to $840 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results